Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.
Identifieur interne : 001B21 ( PubMed/Curation ); précédent : 001B20; suivant : 001B22Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.
Auteurs : G Mani Subramanian [États-Unis] ; Paul A. Moore ; Brian B. Gowen ; Aaron L. Olsen ; Dale L. Barnard ; Jason Paragas ; Robert J. Hogan ; Robert W. SidwellSource :
- Chemotherapy [ 1421-9794 ] ; 2008.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Bioterrorisme, Ebolavirus (), Ebolavirus (physiologie), Interféron alpha (pharmacologie), Interféron bêta (pharmacologie), Interféron de type I (pharmacologie), Lignée cellulaire, Protéines de fusion recombinantes (pharmacologie), Protéines recombinantes, Réplication virale (), Virus du SRAS (), Virus du SRAS (physiologie).
- MESH :
- pharmacologie : Antiviraux, Interféron alpha, Interféron bêta, Interféron de type I, Protéines de fusion recombinantes.
- physiologie : Ebolavirus, Virus du SRAS.
- Animaux, Bioterrorisme, Ebolavirus, Lignée cellulaire, Protéines recombinantes, Réplication virale, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Bioterrorism, Cell Line, Chlorocebus aethiops, Ebolavirus (drug effects), Ebolavirus (physiology), Interferon Type I (pharmacology), Interferon-alpha (pharmacology), Interferon-beta (pharmacology), Recombinant Fusion Proteins (pharmacology), Recombinant Proteins, SARS Virus (drug effects), SARS Virus (physiology), Virus Replication (drug effects).
- MESH :
- chemical , pharmacology : Antiviral Agents, Interferon Type I, Interferon-alpha, Interferon-beta, Recombinant Fusion Proteins.
- drug effects : Ebolavirus, SARS Virus, Virus Replication.
- physiology : Ebolavirus, SARS Virus.
- Animals, Bioterrorism, Cell Line, Chlorocebus aethiops, Recombinant Proteins.
Abstract
The type 1 interferons (INF-alpha and INF-beta) are potent antiviral agents. Albumin-INF-alpha and albumin-INF-beta are novel recombinant proteins consisting of IFN-alpha or IFN-beta genetically fused to human albumin.
DOI: 10.1159/000140361
PubMed: 18560223
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B21
Links to Exploration step
pubmed:18560223Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.</title><author><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G Mani" last="Subramanian">G Mani Subramanian</name><affiliation wicri:level="1"><nlm:affiliation>Human Genome Sciences, Inc., Rockville, MD 20850, USA. Mani_Subramanian@hgsi.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Human Genome Sciences, Inc., Rockville, MD 20850</wicri:regionArea></affiliation></author><author><name sortKey="Moore, Paul A" sort="Moore, Paul A" uniqKey="Moore P" first="Paul A" last="Moore">Paul A. Moore</name></author><author><name sortKey="Gowen, Brian B" sort="Gowen, Brian B" uniqKey="Gowen B" first="Brian B" last="Gowen">Brian B. Gowen</name></author><author><name sortKey="Olsen, Aaron L" sort="Olsen, Aaron L" uniqKey="Olsen A" first="Aaron L" last="Olsen">Aaron L. Olsen</name></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name></author><author><name sortKey="Paragas, Jason" sort="Paragas, Jason" uniqKey="Paragas J" first="Jason" last="Paragas">Jason Paragas</name></author><author><name sortKey="Hogan, Robert J" sort="Hogan, Robert J" uniqKey="Hogan R" first="Robert J" last="Hogan">Robert J. Hogan</name></author><author><name sortKey="Sidwell, Robert W" sort="Sidwell, Robert W" uniqKey="Sidwell R" first="Robert W" last="Sidwell">Robert W. Sidwell</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18560223</idno><idno type="pmid">18560223</idno><idno type="doi">10.1159/000140361</idno><idno type="wicri:Area/PubMed/Corpus">001B21</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B21</idno><idno type="wicri:Area/PubMed/Curation">001B21</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B21</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.</title><author><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G Mani" last="Subramanian">G Mani Subramanian</name><affiliation wicri:level="1"><nlm:affiliation>Human Genome Sciences, Inc., Rockville, MD 20850, USA. Mani_Subramanian@hgsi.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Human Genome Sciences, Inc., Rockville, MD 20850</wicri:regionArea></affiliation></author><author><name sortKey="Moore, Paul A" sort="Moore, Paul A" uniqKey="Moore P" first="Paul A" last="Moore">Paul A. Moore</name></author><author><name sortKey="Gowen, Brian B" sort="Gowen, Brian B" uniqKey="Gowen B" first="Brian B" last="Gowen">Brian B. Gowen</name></author><author><name sortKey="Olsen, Aaron L" sort="Olsen, Aaron L" uniqKey="Olsen A" first="Aaron L" last="Olsen">Aaron L. Olsen</name></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name></author><author><name sortKey="Paragas, Jason" sort="Paragas, Jason" uniqKey="Paragas J" first="Jason" last="Paragas">Jason Paragas</name></author><author><name sortKey="Hogan, Robert J" sort="Hogan, Robert J" uniqKey="Hogan R" first="Robert J" last="Hogan">Robert J. Hogan</name></author><author><name sortKey="Sidwell, Robert W" sort="Sidwell, Robert W" uniqKey="Sidwell R" first="Robert W" last="Sidwell">Robert W. Sidwell</name></author></analytic><series><title level="j">Chemotherapy</title><idno type="eISSN">1421-9794</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Bioterrorism</term><term>Cell Line</term><term>Chlorocebus aethiops</term><term>Ebolavirus (drug effects)</term><term>Ebolavirus (physiology)</term><term>Interferon Type I (pharmacology)</term><term>Interferon-alpha (pharmacology)</term><term>Interferon-beta (pharmacology)</term><term>Recombinant Fusion Proteins (pharmacology)</term><term>Recombinant Proteins</term><term>SARS Virus (drug effects)</term><term>SARS Virus (physiology)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Bioterrorisme</term><term>Ebolavirus ()</term><term>Ebolavirus (physiologie)</term><term>Interféron alpha (pharmacologie)</term><term>Interféron bêta (pharmacologie)</term><term>Interféron de type I (pharmacologie)</term><term>Lignée cellulaire</term><term>Protéines de fusion recombinantes (pharmacologie)</term><term>Protéines recombinantes</term><term>Réplication virale ()</term><term>Virus du SRAS ()</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Interferon Type I</term><term>Interferon-alpha</term><term>Interferon-beta</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Ebolavirus</term><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Interféron bêta</term><term>Interféron de type I</term><term>Protéines de fusion recombinantes</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Ebolavirus</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Ebolavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Bioterrorism</term><term>Cell Line</term><term>Chlorocebus aethiops</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Bioterrorisme</term><term>Ebolavirus</term><term>Lignée cellulaire</term><term>Protéines recombinantes</term><term>Réplication virale</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The type 1 interferons (INF-alpha and INF-beta) are potent antiviral agents. Albumin-INF-alpha and albumin-INF-beta are novel recombinant proteins consisting of IFN-alpha or IFN-beta genetically fused to human albumin.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18560223</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9794</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>3</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Chemotherapy</Title><ISOAbbreviation>Chemotherapy</ISOAbbreviation></Journal><ArticleTitle>Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.</ArticleTitle><Pagination><MedlinePgn>176-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000140361</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The type 1 interferons (INF-alpha and INF-beta) are potent antiviral agents. Albumin-INF-alpha and albumin-INF-beta are novel recombinant proteins consisting of IFN-alpha or IFN-beta genetically fused to human albumin.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The in vitro antiviral activity of albumin-IFN-alpha was evaluated against representative bioterrorism viral agents and the severe acute respiratory syndrome virus. Antiviral activity was assessed using inhibition of cytopathic effect and neutral red staining.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">EC(50) values for albumin-IFN-alpha ranged from <0.1 ng/ml for Punta Toro virus to 65 ng/ml for Venezuelan equine encephalitis virus in the neutral red assay. Albumin-IFN-beta showed 75- and 360-fold greater in vitro activity than albumin-IFN-alpha against Ebola virus and severe acute respiratory syndrome, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Further evaluation of these long-acting albumin-IFN fusion proteins as prophylactic or therapeutic agents against these viral agents of bioterrorism in relevant primate models is warranted.</AbstractText><CopyrightInformation>(c) 2008 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Subramanian</LastName><ForeName>G Mani</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Human Genome Sciences, Inc., Rockville, MD 20850, USA. Mani_Subramanian@hgsi.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Gowen</LastName><ForeName>Brian B</ForeName><Initials>BB</Initials></Author><Author ValidYN="Y"><LastName>Olsen</LastName><ForeName>Aaron L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Barnard</LastName><ForeName>Dale L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Paragas</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hogan</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Sidwell</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01-AI-85348</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Chemotherapy</MedlineTA><NlmUniqueID>0144731</NlmUniqueID><ISSNLinking>0009-3157</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C517868">albumin interferon</NameOfSubstance></Chemical><Chemical><RegistryNumber>77238-31-4</RegistryNumber><NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023482" MajorTopicYN="Y">Bioterrorism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029043" MajorTopicYN="N">Ebolavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>03</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18560223</ArticleId><ArticleId IdType="pii">000140361</ArticleId><ArticleId IdType="doi">10.1159/000140361</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001B21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:18560223
|texte= Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18560223" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |